Swing Trade Stock Picks

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/14/2018 – 05/18/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.70
b. Sell at >~ $10.95

2) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 completion of enrollment announced June 21, 2017. Data to be presented May 17, 2018. – RXI-109-1501 – Dermal scarring – Phase 2; 20180517; 20180517; http://investors.rxipharma.com/news-releases/news-release-details/rxi-pharmaceuticals-present-update-its-clinical-and-cosmetic
2. Phase 2 – Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts); 20180101; 20180531; https://ClinicalTrials.gov/show/NCT02640820
3. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd
4. Phase 2 enrollment completed – noted September 6, 2017. Data to be presented May 18, 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180518; 20180518; http://investors.rxipharma.com/news-releases/news-release-details/rxi-pharmaceuticals-present-update-its-clinical-and-cosmetic

3) CRIS – Curis, Inc.
a. Buy at < ~ $0.47
b. Sell at >~ $1.00
c. Catalysts:
1. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT02812875
2. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
3. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
4. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777

4) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

5) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/14/2018 – 05/18/2018, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 05/11/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $1.00
2. $DCAR – DropCar, Inc. :
   1. Cash/sh = $1.92
3. $EGLT – Egalet Corporation :
   1. Cash/sh = $2.31
4. $FCSC – Fibrocell Science, Inc. :
   1. Cash/sh = $0.77
5. $OPHT – Ophthotech Corporation :
   1. Cash/sh = $4.63
6. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.88
7. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $4.50
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Cash/sh = $3.20
9. $VVUS – VIVUS, Inc. :
   1. Cash/sh = $2.14
10. $VXRT – Vaxart, Inc. :
    1. Cash/sh = $8.50

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 05/11/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $1.73
2. $DCAR – DropCar, Inc. :
   1. Book/sh = $3.01
3. $JAGX – Jaguar Health, Inc. :
   1. Book/sh = $0.57
4. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $3.36
5. $NNDM – Nano Dimension Ltd. :
   1. Book/sh = $1.44
6. $OVAS – OvaScience, Inc. :
   1. Book/sh = $1.80
7. $SEED – Origin Agritech Limited :
   1. Book/sh = $0.76
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $3.16

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/29/2018 – 06/01/2018:

1) ONTX – Onconova Therapeutics, Inc.
a. Buy at < ~ $0.33
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
3. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
4. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
5. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
6. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
7. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443

2) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.61
b. Sell at >~ $10.95

3) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.42
b. Sell at >~ $2.10
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
10. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
11. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
12. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
13. NA – Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT02480972
14. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
15. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
16. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
17. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
27. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
28. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
29. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
30. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
31. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272
32. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
33. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
34. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804

4) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 – Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts); 20180101; 20180531; https://ClinicalTrials.gov/show/NCT02640820
2. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd

5) ALT – Altimmune, Inc.
a. Buy at < ~ $0.41
b. Sell at >~ $1.34
c. Catalysts:
1. Phase 1 – Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B; 20171013; 20180629; https://ClinicalTrials.gov/show/NCT02496897
2. Phase 2 – Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX; 20180307; 20180731; https://ClinicalTrials.gov/show/NCT03232567
3. Phase 1 – NasoShield Study of Safety and Immunogenicity; 20180601; 20190831; https://ClinicalTrials.gov/show/NCT03352466

6) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

7) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/29/2018 - 06/01/2018, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/04/2018 – 06/08/2018:

1) ONTX – Onconova Therapeutics, Inc.
a. Buy at < ~ $0.33
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725
2. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
3. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
4. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
5. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587

2) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.61
b. Sell at >~ $10.95

3) IZEA – IZEA, Inc.
a. Buy at < ~ $1.37
b. Sell at >~ $7.60

4) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.42
b. Sell at >~ $2.10
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
10. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
11. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
12. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
13. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
14. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
15. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
16. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
17. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
27. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
28. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
29. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
30. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
31. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
32. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804
33. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272

5) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd

6) ALT – Altimmune, Inc.
a. Buy at < ~ $0.41
b. Sell at >~ $1.34
c. Catalysts:
1. Phase 1 – Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B; 20171013; 20180629; https://ClinicalTrials.gov/show/NCT02496897
2. Phase 2 – Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX; 20180307; 20180731; https://ClinicalTrials.gov/show/NCT03232567
3. Phase 1 – NasoShield Study of Safety and Immunogenicity; 20180601; 20190831; https://ClinicalTrials.gov/show/NCT03352466

7) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

9) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/04/2018 - 06/08/2018, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/11/2018 – 06/15/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.61
b. Sell at >~ $10.95

2) HMNY – Helios and Matheson Analytics Inc. – Trading Below Cash
a. Buy at < ~ $0.33
b. Sell at >~ $2.00

3) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.42
b. Sell at >~ $2.10
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
10. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
11. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
12. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
13. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
14. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
15. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
16. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
17. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
27. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
28. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
29. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
30. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
31. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
32. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804
33. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272

4) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.90
b. Sell at >~ $6.30
c. Catalysts:
1. Phase 2 enrollment completed – noted September 6, 2017. Full readouts due 1Q/2Q 2018. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20180630; 20180630; http://investors.rxipharma.com/static-files/d04bbf93-5879-49fb-a0da-ae4d2d158ebd

5) CANF – Can-Fite BioPharma Ltd.
a. Buy at < ~ $1.24
b. Sell at >~ $2.70
c. Catalysts:
1. Phase 2 – Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC); 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02128958
2. Phase 2 – A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02927314
3. Phase 2 – A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee; 20181201; 20190131; https://ClinicalTrials.gov/show/NCT00837291

6) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.45

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

8) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/11/2018 – 06/15/2018, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/18/2018 – 06/22/2018:

1) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

2) DFFN – Diffusion Pharmaceuticals Inc.
a. Buy at < ~ $0.44
b. Sell at >~ $0.69
c. Catalysts:
1. NA – Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda; 20181031; 20190228; https://ClinicalTrials.gov/show/NCT03435497
2. NA – Multimodal MRI-guided rTMS to Treat Refractory Hallucinations; 20181101; 20181130; https://ClinicalTrials.gov/show/NCT01373866
3. NA – MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT02988921
4. NA – The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02965963
5. Phase 1 – Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02647983
6. Phase 2 – The Iguratimod Effect on Lupus Nephritis (IGeLU); 20190101; 20190831; https://ClinicalTrials.gov/show/NCT02936375
7. Phase 1 – Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02507583
8. Phase 2 – Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas; 20181201; 20210630; https://ClinicalTrials.gov/show/NCT01966809
9. Phase 2 – MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS); 20171207; 20210521; https://ClinicalTrials.gov/show/NCT01643850
10. NA – Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion; 20180430; 20181031; https://ClinicalTrials.gov/show/NCT03241316
11. Phase 3 – Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation; 20170801; 20180831; https://ClinicalTrials.gov/show/NCT01924065
12. NA – Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy; 20171201; 20180630; https://ClinicalTrials.gov/show/NCT00575432
13. NA – Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial; 20180731; 20181031; https://ClinicalTrials.gov/show/NCT03098732
14. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
15. Phase 2 – Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT01864317
16. NA – Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02178345
17. NA – ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE; 20190201; 20201031; https://ClinicalTrials.gov/show/NCT03296150
18. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
19. Phase 4 – The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals; 20201001; 20211031; https://ClinicalTrials.gov/show/NCT02536846
20. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
21. NA – Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT03436901
22. NA – Development and Validation of Advanced MRI Methods for Clinical Applications; 20220626; 20221026; https://ClinicalTrials.gov/show/NCT03264300
23. Phase 2Phase 3 – Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; 20240104; 20240104; https://ClinicalTrials.gov/show/NCT02004691
24. Early Phase 1 – Brain Dopaminergic Signaling in Opioid Use Disorders; 20201231; 20241231; https://ClinicalTrials.gov/show/NCT03190954
25. Phase 3 – Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects; 20210628; 20220623; https://ClinicalTrials.gov/show/NCT03393000
26. Phase 1 – Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas; 20190601; 20200731; https://ClinicalTrials.gov/show/NCT03054792
27. NA – Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT01974804
28. Phase 4 – Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02853045
29. NA – Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT01542879
30. NA – Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT03268824
31. NA – Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study; 20200331; 20200331; https://ClinicalTrials.gov/show/NCT03169673
32. Phase 1 – Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer; 20191001; 20191031; https://ClinicalTrials.gov/show/NCT03129776
33. NA – Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation; 20191101; 20201130; https://ClinicalTrials.gov/show/NCT02846272

3) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

4) RWLK – ReWalk Robotics Ltd.
a. Buy at < ~ $1.00
b. Sell at >~ $1.30

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/18/2018 – 06/22/2018, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 06/15/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $0.85
2. $EGLT – Egalet Corporation :
   1. Cash/sh = $1.41
3. $HMNY – Helios and Matheson Analytics Inc. :
   1. Cash/sh = $0.52
4. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.88
5. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $4.50
6. $VXRT – Vaxart, Inc. :
   1. Cash/sh = $8.50

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 06/15/2018 include:

1. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $0.95
2. $DCAR – DropCar, Inc. :
   1. Book/sh = $3.01
3. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $3.36
4. $OVAS – OvaScience, Inc. :
   1. Book/sh = $1.80
5. $XGTI – xG Technology, Inc. :
   1. Book/sh = $0.99

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/25/2018 – 06/29/2018:

1) AGRX – Agile Therapeutics, Inc. – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $1.04

2) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

3) PRSS – CafePress Inc. – Trading Below Cash
a. Buy at < ~ $1.26
b. Sell at >~ $1.99

4) IPWR – Ideal Power Inc.
a. Buy at < ~ $1.06
b. Sell at >~ $1.60

5) CHFS – CHF Solutions, Inc.
a. Buy at < ~ $2.50
b. Sell at >~ $3.75
c. Catalysts:
1. Phase 3 – Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation; 20190201; 20190831; https://ClinicalTrials.gov/show/NCT02869022
2. Phase 3 – Digoxin Short Term Treatment Assessment Randomized Trial in AHF; 20181201; 20190630; https://ClinicalTrials.gov/show/NCT02544815
3. Phase 3 – Glutamate for Metabolic Intervention in Coronary Surgery II; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02592824
4. NA – Group Medical Visits in Heart Failure; 20190430; 20190630; https://ClinicalTrials.gov/show/NCT02481921
5. Phase 3 – Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure; 20190301; 20190630; https://ClinicalTrials.gov/show/NCT03458325
6. Phase 2 – Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population; 20190301; 20190301; https://ClinicalTrials.gov/show/NCT02077010
7. Phase 2 – A Dose Ranging Study of CHF 1531 in Asthmatic Subjects; 20180730; 20180730; https://ClinicalTrials.gov/show/NCT03086460
8. Phase 2 – Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction; 20180701; 20190731; https://ClinicalTrials.gov/show/NCT03074591
9. NA – SystemCHANGE™ Intervention on Medication Adherence in Older Adults With Heart Failure; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT03162848
10. Phase 2 – A Study of CLR325 in Chronic Stable Heart Failure Patients.; 20180924; 20180924; https://ClinicalTrials.gov/show/NCT02696967
11. Phase 2 – Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients; 20180801; 20190831; https://ClinicalTrials.gov/show/NCT02362646
12. NA – Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02120014
13. NA – Saline Versus Lactated Ringers Solution: The SOLAR Fluid Trial; 20200901; 20220930; https://ClinicalTrials.gov/show/NCT02565420
14. Phase 2 – Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF (INABLE-Training); 20200401; 20201231; https://ClinicalTrials.gov/show/NCT02713126
15. NA – New Model of Care in Heart Failure; 20200228; 20201231; https://ClinicalTrials.gov/show/NCT03476590
16. Phase 3 – International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device; 20210801; 20210831; https://ClinicalTrials.gov/show/NCT02656329
17. Phase 3 – Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency; 20210101; 20220630; https://ClinicalTrials.gov/show/NCT03037931
18. Phase 1Phase 2 – Diffusion MRI in Heart Failure; 20201201; 20201231; https://ClinicalTrials.gov/show/NCT02973633
19. Phase 2 – Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs; 20191101; 20191130; https://ClinicalTrials.gov/show/NCT02941705
20. NA – Dietetics Education Focused on Malnutrition Prevention; 20190901; 20190930; https://ClinicalTrials.gov/show/NCT02892747
21. NA – Comprehensive Medication Monitoring on Heart Failure Patient Outcomes; 20190701; 20190930; https://ClinicalTrials.gov/show/NCT03519477
22. NA – Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring Randomized Controlled Trial; 20191231; 20200130; https://ClinicalTrials.gov/show/NCT03439384
23. Phase 4 – Albumin in Cardiac Surgery; 20191201; 20200331; https://ClinicalTrials.gov/show/NCT02560519
24. Phase 4 – Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron Deficiency; 20191201; 20191231; https://ClinicalTrials.gov/show/NCT03344523

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/25/2018 – 06/29/2018, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/09/2018 – 07/13/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $10.95

2) RGSE – Real Gds Solar
a. Buy at < ~ $0.37
b. Sell at >~ $1.36

3) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.78
b. Sell at >~ $6.30

4) CBAK – CBAK Energy Technology, Inc.
a. Buy at < ~ $0.85
b. Sell at >~ $2.35

5) GNMX – Aevi Genomic Medicine, Inc.
a. Buy at < ~ $0.98
b. Sell at >~ $2.28
c. Catalysts:
1. Phase 2 – PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03265119
2. – A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03233867
3. Phase 1 – Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohns Disease; 20181001; 20181130; https://ClinicalTrials.gov/show/NCT03169894

6) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

7) CFMS – ConforMIS, Inc.
a. Buy at < ~ $1.15
b. Sell at >~ $1.82

8) IPWR – Ideal Power Inc.
a. Buy at < ~ $1.00
b. Sell at >~ $1.60

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/09/2018 – 07/13/2018, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 07/13/2018 include:

1. $CHFS – CHF Solutions, Inc. :
   1. Cash/sh = $2.35
2. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $0.77
3. $EGLT – Egalet Corporation :
   1. Cash/sh = $1.41
4. $HMNY – Helios and Matheson Analytics Inc. :
   1. Cash/sh = $0.76
5. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.64
6. $PRSS – CafePress Inc. :
   1. Cash/sh = $1.35
7. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $3.49
8. $VXRT – Vaxart, Inc. :
   1. Cash/sh = $8.50

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 07/13/2018 include:

1. $CHFS – CHF Solutions, Inc. :
   1. Book/sh = $3.07
2. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $0.95
3. $DCAR – DropCar, Inc. :
   1. Book/sh = $2.00
4. $JAGX – Jaguar Health, Inc. :
   1. Book/sh = $2.43
5. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $2.94
6. $OSN – Ossen Innovation Co., Ltd. :
   1. Book/sh = $15.50
7. $OVAS – OvaScience, Inc. :
   1. Book/sh = $1.60
8. $PRSS – CafePress Inc. :
   1. Book/sh = $1.93
9. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Book/sh = $2.71
10. $XGTI – xG Technology, Inc. :
    1. Book/sh = $0.99

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/30/2018 – 08/03/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $10.95

2) CBAK – CBAK Energy Technology, Inc.
a. Buy at < ~ $0.85
b. Sell at >~ $2.35

3) GNMX – Aevi Genomic Medicine, Inc.
a. Buy at < ~ $0.83
b. Sell at >~ $2.28
c. Catalysts:
1. Phase 2 – PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03265119
2. – A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03233867
3. Phase 1 – Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohns Disease; 20181001; 20181130; https://ClinicalTrials.gov/show/NCT03169894

4) LIFE – aTyr Pharma, Inc. – Trading Below Cash
a. Buy at < ~ $0.79
b. Sell at >~ $1.32
c. Catalysts:
1. Phase 1Phase 2 – Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy – Study Extension; 20180501; 20180831; https://ClinicalTrials.gov/show/NCT02531217

5) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

6) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.30

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/30/2018 – 08/03/2018, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/06/2018 – 08/10/2018:

1) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $10.95

2) CBAK – CBAK Energy Technology, Inc.
a. Buy at < ~ $0.65
b. Sell at >~ $2.35

3) GNMX – Aevi Genomic Medicine, Inc.
a. Buy at < ~ $0.83
b. Sell at >~ $2.28
c. Catalysts:
1. Phase 2 – PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03265119
2. – A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT03233867
3. Phase 1 – Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohns Disease; 20181001; 20181130; https://ClinicalTrials.gov/show/NCT03169894

4) LIFE – aTyr Pharma, Inc. – Trading Below Cash
a. Buy at < ~ $0.70
b. Sell at >~ $1.32
c. Catalysts:
1. Phase 1Phase 2 – Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy – Study Extension; 20180501; 20180831; https://ClinicalTrials.gov/show/NCT02531217

5) IGLD – Internet Gold – Golden Lines Ltd. – Trading Below Cash
a. Buy at < ~ $2.40
b. Sell at >~ $4.05

6) TISA – Top Image Systems Ltd.
a. Buy at < ~ $0.95
b. Sell at >~ $1.53

7) SUNW – Sunworks, Inc.
a. Buy at < ~ $0.90
b. Sell at >~ $1.30

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/06/2018 – 08/10/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/01/2018 – 10/05/2018:

1) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $1.12
b. Sell at >~ $2.19

2) VBLT – Vascular Biogenics Ltd. – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $3.00
c. Catalysts:
1. VBL Therapeutics to Present at Upcoming Conferences in October; 20181003; 20181011; https://finance.yahoo.com/news/vbl-therapeutics-present-upcoming-conferences-120000385.html
2. Phase 3 – A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL); 20221201; 20230630; https://ClinicalTrials.gov/show/NCT03398655

3) UAVS – AgEagle Aerial Systems, Inc.
a. Buy at < ~ $1.52
b. Sell at >~ $2.22

4) VSAR – Versartis, Inc. – Trading Below Cash
a. Buy at < ~ $1.30
b. Sell at >~ $1.90
c. Catalysts:
1. Phase 3 – A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency; 20190930; 20200131; https://ClinicalTrials.gov/show/NCT03145831
2. Phase 2 – Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD; 20191201; 20191231; https://ClinicalTrials.gov/show/NCT02719990

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 10/01/2018 – 10/05/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/08/2018 – 10/12/2018:

1) RXII – RXi Pharmaceuticals Corporation
a. Buy at < ~ $0.55
b. Sell at >~ $2.19

2) VBLT – Vascular Biogenics Ltd. – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $3.00
c. Catalysts:
1. VBL Therapeutics to Present at Upcoming Conferences in October; 20181003; 20181011; https://finance.yahoo.com/news/vbl-therapeutics-present-upcoming-conferences-120000385.html
2. Phase 3 – A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL); 20221201; 20230630; https://ClinicalTrials.gov/show/NCT03398655

3) CFMS – Conformis, Inc.
a. Buy at < ~ $0.88
b. Sell at >~ $1.30

4) VSAR – Versartis, Inc. – Trading Below Cash
a. Buy at < ~ $1.30
b. Sell at >~ $1.90
c. Catalysts:
1. Phase 3 – A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency; 20190930; 20200131; https://ClinicalTrials.gov/show/NCT03145831
2. Phase 2 – Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD; 20191201; 20191231; https://ClinicalTrials.gov/show/NCT02719990

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 10/08/2018 – 10/12/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/15/2018 – 10/19/2018:

1) VBLT – Vascular Biogenics Ltd. – Trading Below Cash
a. Buy at < ~ $1.38
b. Sell at >~ $3.00
c. Catalysts:
1. Phase 3 – A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL); 20221201; 20230630; https://ClinicalTrials.gov/show/NCT03398655

2) ADXS – Advaxis, Inc.
a. Buy at < ~ $0.64
b. Sell at >~ $1.15
c. Catalysts:
1. Phase 1Phase 2 – ADXS11-001 High Dose HPV+ Cervical Cancer; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02164461
2. Phase 2 – A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy; 20190301; 20190331; https://ClinicalTrials.gov/show/NCT02531854
3. Phase 2 – Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer; 20181002; 20181031; https://ClinicalTrials.gov/show/NCT01266460
4. Phase 1Phase 2 – Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors; 20180801; 20181231; https://ClinicalTrials.gov/show/NCT02386501
5. Phase 2 – ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer; 20180801; 20190831; https://ClinicalTrials.gov/show/NCT02002182
6. Phase 2 – Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal; 20200301; 20220331; https://ClinicalTrials.gov/show/NCT02399813
7. Phase 3 – Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer; 20200601; 20210630; https://ClinicalTrials.gov/show/NCT02853604
8. Phase 1 – Expressing Personalized Tumor Antigens Study; 20190901; 20200930; https://ClinicalTrials.gov/show/NCT03265080
9. Phase 1Phase 2 – ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer – KEYNOTE-046; 20190401; 20191231; https://ClinicalTrials.gov/show/NCT02325557
10. Phase 1Phase 2 – Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer; 20190701; 20191231; https://ClinicalTrials.gov/show/NCT02291055

3) CFMS – Conformis, Inc.
a. Buy at < ~ $0.88
b. Sell at >~ $1.30

4) CYCC – Cyclacel Pharmaceuticals, Inc. – Trading Below Cash
a. Buy at < ~ $1.28
b. Sell at >~ $1.80
c. Catalysts:
1. Phase 1 trial presented at AACR April 15, 2018. Updated data due 2018. – CYC065 – Advanced cancers – Phase 1; 20181231; 20181231; http://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-reports-first-quarter-2018-financial
2. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Phase 1Phase 2 – Olaparib + Sapacitabine in BRCA Mutant Breast Cancer; 20200622; 20250622; https://ClinicalTrials.gov/show/NCT03641755
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 10/15/2018 – 10/19/2018, and Why?

Disclaimer

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 10/19/2018 include:

1. $ATOS – Atossa Genetics Inc. :
   1. Cash/sh = $1.71
2. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $0.70
3. $DCAR – DropCar, Inc. :
   1. Cash/sh = $0.88
4. $HMNY – Helios and Matheson Analytics Inc. :
   1. Cash/sh = $0.02
5. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.55
6. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $2.81
7. $TCON – TRACON Pharmaceuticals, Inc. :
   1. Cash/sh = $1.79
8. $TRVN – Trevena, Inc. :
   1. Cash/sh = $0.85
9. $VXRT – Vaxart, Inc. :
   1. Cash/sh = $3.24

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/19/2018 include:

1. $ATOS – Atossa Genetics Inc. :
   1. Book/sh = $1.98
2. $CHFS – CHF Solutions, Inc. :
   1. Book/sh = $1.96
3. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $0.87
4. $DCAR – DropCar, Inc. :
   1. Book/sh = $2.00
5. $HMNY – Helios and Matheson Analytics Inc. :
   1. Book/sh = $113.81
6. $IPWR – Ideal Power Inc. :
   1. Book/sh = $0.60
7. $JAGX – Jaguar Health, Inc. :
   1. Book/sh = $1.23
8. $KOOL – Cesca Therapeutics Inc. :
   1. Book/sh = $0.67
9. $OSN – Ossen Innovation Co., Ltd. :
   1. Book/sh = $15.50
10. $OVAS – OvaScience, Inc. :
    1. Book/sh = $1.40
11. $RTTR – Ritter Pharmaceuticals, Inc. :
    1. Book/sh = $2.11
12. $RXII – RXi Pharmaceuticals Corporation :
    1. Book/sh = $0.80
13. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Book/sh = $1.89
14. $XGTI – xG Technology, Inc. :
    1. Book/sh = $0.69

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/19/2018 – 11/23/2018:

1) ACHV – Achieve Life Sciences, Inc. – Trading Below Cash
a. Buy at < ~ $1.70
b. Sell at >~ $5.20
c. Catalysts:
1. NA – In Vitro And Ex Vivo Anti-Inflammatory Activities Of Salmon Polar Lipids; 20181031; 20181130; https://ClinicalTrials.gov/show/NCT03603769
2. Phase 2 – Trial of Cytisine in Adult Smokers; 20190512; 20190630; https://ClinicalTrials.gov/show/NCT03709823

2) OXBR – Oxbridge Re Holdings Limited – Trading Below Cash
a. Buy at < ~ $1.00
b. Sell at >~ $2.50

3) ADXS – Advaxis, Inc. – Trading Below Cash
a. Buy at < ~ $0.44
b. Sell at >~ $1.15
c. Catalysts:
1. Phase 1Phase 2 – ADXS11-001 High Dose HPV+ Cervical Cancer; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02164461
2. Phase 2 – A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy; 20190301; 20190331; https://ClinicalTrials.gov/show/NCT02531854
3. Phase 1Phase 2 – Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors; 20180801; 20181231; https://ClinicalTrials.gov/show/NCT02386501
4. Phase 2 – ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer; 20180801; 20190831; https://ClinicalTrials.gov/show/NCT02002182
5. Phase 1Phase 2 – ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer – KEYNOTE-046; 20190401; 20191231; https://ClinicalTrials.gov/show/NCT02325557
6. Phase 2 – Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal; 20200301; 20220331; https://ClinicalTrials.gov/show/NCT02399813
7. Phase 3 – Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer; 20200601; 20210630; https://ClinicalTrials.gov/show/NCT02853604
8. Phase 1Phase 2 – Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer; 20190701; 20191231; https://ClinicalTrials.gov/show/NCT02291055
9. Phase 1 – Expressing Personalized Tumor Antigens Study; 20190901; 20200930; https://ClinicalTrials.gov/show/NCT03265080

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 11/19/2018 – 11/23/2018, and Why?

Disclaimer

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 11/16/2018 include:

1. $ATOS – Atossa Genetics Inc. :
   1. Cash/sh = $1.71
2. $CFMS – Conformis, Inc. :
   1. Cash/sh = $0.73
3. $CLDX – Celldex Therapeutics, Inc. :
   1. Cash/sh = $0.69
4. $CYCC – Cyclacel Pharmaceuticals, Inc. :
   1. Cash/sh = $1.65
5. $IPWR – Ideal Power Inc. :
   1. Cash/sh = $0.49
6. $LIFE – aTyr Pharma, Inc. :
   1. Cash/sh = $2.00
7. $OVAS – OvaScience, Inc. :
   1. Cash/sh = $1.45
8. $RTTR – Ritter Pharmaceuticals, Inc. :
   1. Cash/sh = $2.88
9. $TCON – TRACON Pharmaceuticals, Inc. :
   1. Cash/sh = $1.79
10. $TRVN – Trevena, Inc. :
    1. Cash/sh = $0.94
11. $VBLT – Vascular Biogenics Ltd. :
    1. Cash/sh = $1.71
12. $VXRT – Vaxart, Inc. :
    1. Cash/sh = $2.96

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

#TradingBelowCash #TBC #StockPicks #Stock #Market #Trading

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 11/16/2018 include:

1. $ATOS – Atossa Genetics Inc. :
   1. Book/sh = $1.98
2. $CFMS – Conformis, Inc. :
   1. Book/sh = $0.82
3. $CHFS – CHF Solutions, Inc. :
   1. Book/sh = $1.96
4. $CLDX – Celldex Therapeutics, Inc. :
   1. Book/sh = $0.87
5. $CYCC – Cyclacel Pharmaceuticals, Inc. :
   1. Book/sh = $1.55
6. $DCAR – DropCar, Inc. :
   1. Book/sh = $1.15
7. $DTEA – DAVIDsTEA Inc. :
   1. Book/sh = $2.65
8. $HMNY – Helios and Matheson Analytics Inc. :
   1. Book/sh = $113.81
9. $IPWR – Ideal Power Inc. :
   1. Book/sh = $0.60
10. $JAGX – Jaguar Health, Inc. :
    1. Book/sh = $1.23
11. $KOOL – Cesca Therapeutics Inc. :
    1. Book/sh = $0.67
12. $LIFE – aTyr Pharma, Inc. :
    1. Book/sh = $1.52
13. $OSN – Ossen Innovation Co., Ltd. :
    1. Book/sh = $15.50
14. $OVAS – OvaScience, Inc. :
    1. Book/sh = $1.40
15. $RTTR – Ritter Pharmaceuticals, Inc. :
    1. Book/sh = $2.11
16. $RXII – RXi Pharmaceuticals Corporation :
    1. Book/sh = $0.80
17. $TISA – Top Image Systems Ltd. :
    1. Book/sh = $0.78
18. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Book/sh = $1.43
19. $VBLT – Vascular Biogenics Ltd. :
    1. Book/sh = $2.03
20. $VXRT – Vaxart, Inc. :
    1. Book/sh = $3.13
21. $XGTI – xG Technology, Inc. :
    1. Book/sh = $0.69

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/26/2018 – 11/30/2018:

1) ACHV – Achieve Life Sciences, Inc. – Trading Below Cash
a. Buy at < ~ $1.53
b. Sell at >~ $5.20
c. Catalysts:
1. NA – In Vitro And Ex Vivo Anti-Inflammatory Activities Of Salmon Polar Lipids; 20181031; 20181130; https://ClinicalTrials.gov/show/NCT03603769
2. Phase 2 – Trial of Cytisine in Adult Smokers; 20190512; 20190630; https://ClinicalTrials.gov/show/NCT03709823

2) OXBR – Oxbridge Re Holdings Limited – Trading Below Cash
a. Buy at < ~ $0.93
b. Sell at >~ $2.50

3) ADXS – Advaxis, Inc. – Trading Below Cash
a. Buy at < ~ $0.42
b. Sell at >~ $1.15
c. Catalysts:
1. Phase 1Phase 2 – ADXS11-001 High Dose HPV+ Cervical Cancer; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02164461
2. Phase 2 – A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy; 20190301; 20190331; https://ClinicalTrials.gov/show/NCT02531854
3. Phase 1Phase 2 – Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors; 20180801; 20181231; https://ClinicalTrials.gov/show/NCT02386501
4. Phase 2 – ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer; 20180801; 20190831; https://ClinicalTrials.gov/show/NCT02002182
5. Phase 1Phase 2 – ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer – KEYNOTE-046; 20190401; 20191231; https://ClinicalTrials.gov/show/NCT02325557
6. Phase 2 – Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal; 20200301; 20220331; https://ClinicalTrials.gov/show/NCT02399813
7. Phase 3 – Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer; 20200601; 20210630; https://ClinicalTrials.gov/show/NCT02853604
8. Phase 1Phase 2 – Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer; 20190701; 20191231; https://ClinicalTrials.gov/show/NCT02291055
9. Phase 1 – Expressing Personalized Tumor Antigens Study; 20190901; 20200930; https://ClinicalTrials.gov/show/NCT03265080

4) OMED – OncoMed Pharmaceuticals, Inc. – Trading Below Cash
a. Buy at < ~ $1.31
b. Sell at >~ $3.25
c. Catalysts:
1. Phase 1 – A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors; 20190501; 20191031; https://ClinicalTrials.gov/show/NCT03119428
2. Phase 1 – A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT03035253
3. Phase 1 – A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors; 20191201; 20200630; https://ClinicalTrials.gov/show/NCT03295942
4. Phase 1 – A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer; 20190601; 20191231; https://ClinicalTrials.gov/show/NCT03030287

5) EDGE – Edge Therapeutics, Inc. – Trading Below Cash
a. Buy at < ~ $0.65
b. Sell at >~ $1.18
c. Catalysts:
1. Phase 3 – Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT03345771
2. Phase 3 – Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT03237637
3. NA – Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03347383
4. Phase 2 – Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques; 20190131; 20200601; https://ClinicalTrials.gov/show/NCT02784210
5. NA – Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT03187418
6. NA – Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer; 20180701; 20181231; https://ClinicalTrials.gov/show/NCT01657617
7. NA – Low-level Laser Therapy Versus High Frequency on Pressure Ulcers Treatment; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT02296697
8. Phase 3 – An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062); 20150610; 20181208; https://ClinicalTrials.gov/show/NCT02105688
9. – Restorelle® Mesh Versus Native Tissue Repair for Prolapse; 20180501; 20211130; https://ClinicalTrials.gov/show/NCT02162615
10. NA – Low-level Light Therapy on Treatment of Venous Ulcers Assesed by Nursing Outcome Classification (NOC); 20180701; 20181231; https://ClinicalTrials.gov/show/NCT03229330
11. NA – A New Treatment for Zenkers Diverticulum-submucosal Tunneling Endoscopic Septum Division; 20180614; 20190514; https://ClinicalTrials.gov/show/NCT03125733
12. NA – Assessment of Chiropractic Treatment: Strength and Balance; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT02670148
13. NA – Word Learning in Children With Autism; 20210531; 20210531; https://ClinicalTrials.gov/show/NCT03419611
14. – GIse Registry Of Transcatheter Treatment of Mitral Valve regurgitaTiOn (GIOTTO); 20210201; 20210201; https://ClinicalTrials.gov/show/NCT03521921
15. NA – Systematic Light Exposure to Treat Cancer-Related Fatigue; 20220430; 20220430; https://ClinicalTrials.gov/show/NCT03217201
16. – A Trial on the Opportunity and Treatment of Residual Deformity After Reduction in Developmental Dislocation of the Hip; 20241201; 20241231; https://ClinicalTrials.gov/show/NCT02163603
17. Phase 1 – Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Patient Outcomes for Locally Advanced Lung and Brain Tumor Patients Treated With Proton Therapy; 20220531; 20220531; https://ClinicalTrials.gov/show/NCT03403361
18. NA – A Multicenter Trial of PLA vs. Surgery for Treating PTMC; 20201231; 20221231; https://ClinicalTrials.gov/show/NCT03377829
19. NA – Above-versus Below-elbow Casting for Conservative Treatment of Distal Radius Fractures; 20190402; 20191215; https://ClinicalTrials.gov/show/NCT03126175
20. – PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility; 20190301; 20190331; https://ClinicalTrials.gov/show/NCT03026309
21. NA – Light Therapy and Binge Eating Disorder Treatment (BED Light Study); 20191029; 20191029; https://ClinicalTrials.gov/show/NCT03094260
22. – Negative Pressure Wound Therapy Registry; 20200101; 20200131; https://ClinicalTrials.gov/show/NCT02467998
23. – Effect of miR-200b on Diabetic Wounds; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02581098

6) LIFE – aTyr Pharma, Inc. – Trading Below Cash
a. Buy at < ~ $0.49
b. Sell at >~ $0.82
c. Catalysts:
1. In the fourth quarter of 2018, aTyr plans to initiate a Phase 1b/2a multiple-ascending dose, placebo-controlled, first-in-patient study with ATYR1923 …; 20181001; 20181231; https://finance.yahoo.com/news/atyr-pharma-announces-pulmonary-sarcoidosis-200500950.html

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 11/26/2018 – 11/30/2018, and Why?

Disclaimer

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/03/2018 – 12/07/2018:

1) ACHV – Achieve Life Sciences, Inc. – Trading Below Cash
a. Buy at < ~ $1.51
b. Sell at >~ $5.20
c. Catalysts:
1. Phase 2 – Trial of Cytisine in Adult Smokers; 20190512; 20190630; https://ClinicalTrials.gov/show/NCT03709823

2) ARCW – ARC Group Worldwide, Inc.
a. Buy at < ~ $1.05
b. Sell at >~ $2.60

3) LIFE – aTyr Pharma, Inc. – Trading Below Cash
a. Buy at < ~ $0.49
b. Sell at >~ $0.82
c. Catalysts:
1. In the fourth quarter of 2018, aTyr plans to initiate a Phase 1b/2a multiple-ascending dose, placebo-controlled, first-in-patient study with ATYR1923 …; 20181001; 20181231; https://finance.yahoo.com/news/atyr-pharma-announces-pulmonary-sarcoidosis-200500950.html

4) KOPN – Kopin Corporation
a. Buy at < ~ $1.54
b. Sell at >~ $1.95

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks < ~ $10 to Buy next week, 12/03/2018 – 12/07/2018, and Why?

Disclaimer

[Author]

Posts